Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 961 to 970 of 1535 total matches.
Drugs for Helicobacter pylori Infection
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
information call: 800-211-2769
114
The Medical Letter ® Vol. 59 (1525) July 17, 2017
higher with bismuth ...
About 50% of the world’s population is infected with
Helicobacter pylori. These gastric bacteria can cause
chronic inflammation and have been associated with
development of gastritis, peptic ulcer disease, gastric
adenocarcinoma, and gastric mucosa-associated
lymphoid tissue (MALT) lymphoma. Eradication of H.
pylori can promote gastric healing, prevent recurrence
of duodenal and gastric ulcers, and reduce the
incidence of gastric cancer. Guidelines for treatment
of H. pylori infection were updated recently.
Management of Opioid Withdrawal Symptoms
The Medical Letter on Drugs and Therapeutics • Aug 27, 2018 (Issue 1554)
.
For further information call: 800-211-2769
138
The Medical Letter ® Vol. 60 (1554) August 27, 2018
Table 1 ...
Pharmacologic management of opioid withdrawal
symptoms can reduce the intensity of drug craving
and improve treatment retention in patients with opioid
use disorder who will receive maintenance treatment.
Withdrawal management without subsequent maintenance
treatment is associated with high rates of
relapse, overdose death, and HIV and/or hepatitis C
virus infection. Several guidelines on management
of opioid withdrawal are available. Maintenance
treatment of opioid use disorder was reviewed in a
previous issue.
Esketamine Nasal Spray (Spravato) for Treatment-Resistant Depression
The Medical Letter on Drugs and Therapeutics • Apr 08, 2019 (Issue 1569)
The Medical Letter ® Vol. 61 (1569) April 8, 2019
taking the same regimen or switch to an intranasal
placebo ...
The FDA has approved esketamine (Spravato –
Janssen), an N-methyl-D-aspartate (NMDA) receptor
antagonist, for intranasal treatment (in conjunction
with an oral antidepressant) of adults with treatment-resistant
depression (TRD). This is the first FDA
approval for esketamine, which is the S-enantiomer
of the intravenous anesthetic ketamine (Ketalar,
and generics). In recent years, IV ketamine has been
increasingly used (off-label) for treatment of TRD.
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
The Medical Letter on Drugs and Therapeutics • Mar 09, 2020 (Issue 1593)
hours 5-7 hours
36
The Medical Letter ® Vol. 62 (1593) March 9, 2020
to mild or none) at 2 hours ...
Lasmiditan (Reyvow – Lilly), an oral serotonin
(5-HT1F) receptor agonist, and ubrogepant (Ubrelvy –
Allergan), an oral calcitonin gene-related peptide
(CGRP) receptor antagonist, have been approved
by the FDA for acute treatment of migraine with or
without aura in adults.
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
were excluded, as were those with a history
178
The Medical Letter ® Vol. 60 (1559) November 5, 2018 ...
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and galcanezumab
are the second and third subcutaneously
injected monoclonal antibodies that target the CGRP
pathway to be approved by the FDA for this indication;
erenumab-aooe (Aimovig), which targets the CGRP
receptor, was the first.
Istradefylline (Nourianz) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020 (Issue 1591)
.
21
The Medical Letter ® Vol. 62 (1591) February 10, 2020
Table 3. Some Drugs for Parkinson’s ...
The FDA has approved istradefylline (Nourianz —
Kyowa Kirin), an oral adenosine A2A receptor antagonist,
for use as an adjunct to carbidopa/levodopa in adults
with Parkinson's disease (PD) who experience "off"
episodes. Istradefylline is the first adenosine A2A
receptor antagonist to be approved in the US; it has
been available in Japan since 2013.
Two Vonoprazan Combinations (Voquezna) for H. pylori
The Medical Letter on Drugs and Therapeutics • Oct 31, 2022 (Issue 1662)
copackaged with amoxicillin and with both amoxicillin
and clarithromycin.
The Medical Letter ® Vol. 64 ...
The FDA has approved vonoprazan, a potassium-competitive
acid blocker, copackaged with amoxicillin
(Voquezna Dual Pak – Phathom) and with amoxicillin
and clarithromycin (Voquezna Triple Pak) for
treatment of Helicobacter pylori infection in adults.
Vonoprazan is the first potassium-competitive acid
blocker to be approved in the US. It has been available
in Japan for treatment of various acid-related
disorders since 2014. Vonoprazan is not available
alone in the US.
Immunization of College Students Against Meningococcal Disease
The Medical Letter on Drugs and Therapeutics • Aug 07, 2000 (Issue 1084)
Street, New Rochelle, N.Y. 10801 • A Nonprofit Publication
Vol. 42 (W1084A)
August 7, 2000
REPRODUCED ...
The US Public Health Service Advisory Committee on Immunization Practices has recently published new recommendations for prevention and control of meningococcal disease in college students.
Ceritinib (Zykadia) for Non-Small Cell Lung Cancer
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
of
ceritinib on progression-free and overall survival
remains to be determined.
63
The Medical Letter ® Vol ...
Ceritinib (Zykadia – Novartis), an oral tyrosine
kinase inhibitor, has received accelerated approval
from the FDA for treatment of patients with anaplastic
lymphoma kinase (ALK)-positive metastatic
non-small cell lung cancer (NSCLC) who have
progressed on or are intolerant to crizotinib (Xalkori).
It is the second tyrosine kinase inhibitor to be approved
for ALK-positive metastatic NSCLC; crizotinib was the
first. Translocations of the ALK gene are found in
about 5% of lung cancers; they occur predominantly
in nonsmokers with adenocarcinoma.
A Transcutaneous Electrical Nerve Stimulation Device (Cefaly) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014 (Issue 1449)
.
74
The Medical Letter ® Vol. 56 (1449) August 18, 2014
1. Approximate cost according ...
The FDA has approved the use of a transcutaneous
electrical nerve stimulation device (Cefaly – Cefaly
Technology) for prevention of episodic migraine in
patients ≥18 years old. The first device to be approved
in the US for migraine prevention, it is available in
Canada and Europe for treatment and prevention of
migraines. A transcranial magnetic stimulation device
(SpringTMS - eNeura Therapeutics) recently approved
by the FDA for treatment of migraine preceded by aura
will be reviewed in a future issue.